 |
|
|
| |
Directly observed therapy for hepatitis C with sofosbuvir/velpatasvir alongside opioid substitution as a tailored microelimination strategy in PWIDs with a high risk of nonadherence
- real-world data from Vienna, Austria
|
| |
| |
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Caroline Schmidbauer1,2,3, Raphael Schubert4, Angelika Schütz4,
Cornelia Schwanke4, Enisa Gutic1, Roxana Pirker1, Tobias Lang1,
Thomas Reiberger2,3, Hans Haltmayer4, Michael Gschwantler1,5.
1Wilhelminenspital, Department of Internal Medicine IV, Vienna,
Austria; 2Medical University of Vienna, Department of Internal Medicine
III, Division of Gastroenterology and Hepatology, Vienna, Austria;
3Vienna HIV & Liver Study Group, Vienna, Austria; 4Suchthilfe Wien
gGmbH, Ambulatorium Suchthilfe Wien, Vienna, Austria; 5Sigmund
Freud University, Vienna, Austria
|
| |
|
|
|
|
|
